Deep Vein Thrombosis

Introduction

Deep vein thrombosis (DVT) is a serious medical condition characterized by the formation of a blood clot (thrombus) in one or more deep veins, most commonly in the legs.^[1]It is a major manifestation of venous thromboembolism (VTE), a broader term encompassing both DVT and pulmonary embolism (PE).^[2]VTE is recognized as a common and clinically significant cardiovascular condition, ranking as the third most frequent life-threatening cardiovascular event after coronary heart disease and stroke.^[2]

Background and Biological Basis

The formation of a DVT typically involves disruptions in blood flow, damage to the vein wall, or an increased tendency for blood to clot, a concept known as Virchow’s triad. These clots can partially or completely block blood flow, leading to pain, swelling, and tenderness in the affected limb. The biological processes underlying DVT involve complex interactions within the coagulation and fibrinolysis pathways, which regulate blood clotting and clot dissolution. Genetic factors play a substantial role in an individual’s susceptibility to DVT, with heritability estimates for VTE ranging from 0.5 to 0.6.^[2] Numerous genetic variants have been consistently linked to VTE, particularly those involved in these critical pathways.^[2] For instance, specific gene variants like those in the F11locus have been associated with deep vein thrombosis.^[3] Recent research has also implicated specific loci, such as ZFPM2, and identified obesity as a causal risk factor for DVT.^{[4], [5]}

Clinical Relevance

DVT poses significant clinical challenges due to its potential for severe complications. The most life-threatening complication is pulmonary embolism (PE), which occurs when a part of the blood clot breaks off and travels to the lungs, blocking blood flow. PE can be fatal, with an estimated 600,000 hospitalizations and 60,000 deaths occurring annually in the United States.^[2]Other long-term complications of DVT include post-thrombotic syndrome, characterized by chronic pain, swelling, and skin changes in the affected limb, significantly impacting quality of life. Early diagnosis and appropriate management are crucial to prevent these serious outcomes.

Social Importance

Given its prevalence and potential for severe morbidity and mortality, DVT and VTE represent a substantial public health concern.^[6] Approximately 2 million adults in the United States alone develop DVT each year.^[2] Beyond the direct health impacts, the condition also imposes a considerable economic burden, including costs associated with acute treatment, long-term care for complications like post-thrombotic syndrome, and lost productivity.^[7] Understanding the genetic and environmental factors contributing to DVT is vital for developing effective prevention strategies, improving diagnostic tools, and advancing personalized treatment approaches.

Methodological and Statistical Constraints

Genetic studies of deep vein thrombosis (DVT) and venous thromboembolism (VTE) face inherent methodological and statistical challenges that influence the interpretation and generalizability of their findings. A significant limitation concerns study power, as detecting genetic variants with modest effect sizes often requires very large sample cohorts, with estimates suggesting over 20,000 patients are needed to identify genome-wide significant odds ratios around 1.10.^[8] Many studies, particularly earlier ones, have not reached such sample sizes, potentially leading to an underestimation of the full genetic architecture of DVT.^[8] Furthermore, while genome-wide association studies (GWAS) have identified novel loci, common susceptibility alleles found through these approaches are generally not expected to contribute as strongly to VTE risk as established factors like the FV and ABO loci, indicating that the most impactful genetic factors may already be known.^[9] Cohort selection and statistical matching can also introduce bias. For instance, some studies have used controls that were not specifically matched to DVT cases for demographic factors such as gender and sex.^[8] Although analyses often suggest a modest influence of such imperfect matching on identified loci, it can still impact the precision and generalizability of risk estimates. The reliance on statistical imputation for ungenotyped SNPs also carries a degree of uncertainty, as the quality of imputation (e.g., r.^[10] hat.0.3) can vary and affect the confidence in detected associations.^[8]

Phenotypic Heterogeneity and Population Generalizability

The definition and of DVT and VTE can introduce heterogeneity, affecting the consistency and comparability of findings across studies. Some research aggregates DVT with pulmonary embolism (PE) under the broader term VTE, encompassing events in the leg or arm, which may obscure variant effects specific to DVT alone.^[11] Additionally, reliance on self-reported events for thrombosis in large cohorts, while efficient for scale, may introduce misclassification bias compared to objectively confirmed diagnoses.^[12] Population ancestry significantly impacts the generalizability of genetic findings. Many large-scale genetic studies, including those for DVT, have predominantly focused on individuals of European ancestry.^[13] which limits the direct applicability of identified risk variants to other populations. While studies are emerging that explore VTE susceptibility variants in diverse groups, such as African-Americans.^[11] the breadth of genetic diversity across global populations is still underrepresented. Furthermore, studies often exclude individuals with known high-penetrance genetic mutations like FV Leiden or FII20210A, or deficiencies in anti-thrombin, protein C, or protein S.^[8] While this exclusion helps to focus on novel common variants, it means the findings may not fully represent the genetic landscape of DVT in individuals with these established, strong genetic predispositions.

Unaccounted Heritability and Complex Interactions

Despite significant progress in identifying genetic loci associated with DVT, a substantial portion of the disease’s heritability remains unexplained by common single nucleotide polymorphisms (SNPs) identified through GWAS. This “missing heritability” is a pervasive challenge in complex diseases.^[14] suggesting that other genetic architectures, such as rare variants, structural variations, or complex haplotype effects, may contribute to DVT risk but are not fully captured by current GWAS methodologies.^[4] While methods for estimating heritability from dense genotype data and imputed variants are improving.^[15] fully accounting for the genetic variance of DVT is an ongoing area of research.

DVT is a multicausal disease, influenced by a complex interplay of genetic, environmental, and physiological risk factors.^[16]Current genetic studies often focus primarily on genetic associations, making it challenging to fully delineate the intricate gene-environment interactions that contribute to disease risk. For example, while obesity has been implicated as a causal risk factor for VTE.^[4]the precise mechanisms of how genetic predispositions interact with environmental factors like lifestyle, comorbidities, or acute triggers are still being deciphered. Further research is needed to comprehensively integrate these complex interactions into predictive models and enhance our understanding of DVT pathogenesis.^[17]

Variants

Genetic variations play a significant role in an individual’s susceptibility to deep vein thrombosis (DVT), a condition characterized by blood clots forming in deep veins, often in the legs. Key genes involved in the coagulation cascade, such as Factor V (F5) and Factor II (F2, also known as prothrombin), harbor some of the most well-established genetic risk factors. The rs6025 variant in F5, commonly known as Factor V Leiden, is a well-known genetic predisposition to DVT, leading to a modified protein that is resistant to inactivation by activated protein C, thereby increasing clotting risk.^[1] Similarly, the rs1799963 variant in F2, known as prothrombin G20210A, is another major genetic risk factor that leads to elevated prothrombin levels, enhancing the overall clotting potential and significantly increasing DVT risk.^[1] The ABO gene, which determines blood group, is also a critical modulator of DVT risk, with non-O blood types (A, B, AB) generally associated with higher levels of von Willebrand factor and Factor VIII, both of which increase thrombotic risk.^[9] Variants like rs115478735 , rs687289 , and rs529565 within the ABO locus are implicated in influencing these circulating coagulation factor levels and, consequently, DVT susceptibility.

Further impacting the coagulation cascade are variants within F11 (Factor XI), a protein involved in the intrinsic pathway of blood coagulation. Genetic variations such as rs56810541 and rs2036914 in F11 can influence Factor XI activity, and some alleles have been associated with altered DVT risk.^[18] The rs4444878 variant, located in the F11-AS1 (Factor XI antisense RNA 1) region, may indirectly affect F11 expression or function, thereby potentially modulating coagulation. Fibrinogen, a crucial protein for clot formation, is composed of three chains encoded by genes including FGA (Fibrinogen Alpha Chain) and FGG (Fibrinogen Gamma Chain). Intergenic variants like rs7659024 (between FGA and FGG) and rs7654093 (between FGG and LRAT) can influence fibrinogen levels or the structure of the resulting fibrin clot, impacting its stability and overall thrombotic potential.

Beyond the direct coagulation factors, recent genome-wide association studies (GWAS) have identified novel susceptibility loci for venous thromboembolism (VTE), including deep vein thrombosis. For instance, theTSPAN15 (Tetraspanin 15) gene, involved in cell surface organization and signaling, harbors variants such as rs78707713 and rs17490626 which have been identified as susceptibility loci for VTE.^[19] The common T allele of rs78707713 is associated with an increased risk of VTE, and this intronic variant is in strong linkage disequilibrium with rs17490626 , which is predicted to map to an enhancer domain.^[19] Other genes, such as ATP1B1 (ATPase Na+/K+ Transporting Subunit Beta 1), which is involved in maintaining cellular ion gradients, and SLC19A2(Solute Carrier Family 19 Member 2), a thiamine transporter, have also been implicated through variants likers145163454 and rs1894692 , respectively, suggesting broader genetic influences on DVT risk beyond the classical coagulation pathways.^[1] These findings highlight the complex genetic architecture underlying DVT and the importance of both established and novel genetic factors.

Key Variants

RS ID	Gene	Related Traits
rs145163454	ATP1B1	hemorrhoid venous thromboembolism thrombophilia blood coagulation disease deep vein thrombosis
rs1894692	SLC19A2 - F5	pneumonia blood protein amount atrial fibrillation tissue factor pathway inhibitor amount endometriosis
rs115478735 rs687289 rs529565	ABO	atrial fibrillation low density lipoprotein cholesterol , lipid low density lipoprotein cholesterol low density lipoprotein cholesterol , phospholipid amount cholesteryl ester , intermediate density lipoprotein
rs6025 rs6032	F5	venous thromboembolism deep vein thrombosis inflammatory bowel disease peripheral arterial disease peripheral vascular disease
rs4444878	F11-AS1	deep vein thrombosis cardioembolic stroke heart disease pulmonary embolism, Pulmonary Infarction
rs1799963	F2	venous thromboembolism deep vein thrombosis prothrombin amount venous thromboembolism, factor VII venous thromboembolism, von Willebrand factor quality
rs7659024	FGA - FGG	venous thromboembolism deep vein thrombosis chronic thromboembolic pulmonary hypertension
rs7654093	FGG - LRAT	deep vein thrombosis thrombophilia
rs56810541 rs2036914	F11	intracranial thrombosis blood coagulation trait encounter with health service deep vein thrombosis Phlebitis, Thrombophlebitis
rs78707713 rs17490626	TSPAN15	venous thromboembolism pulmonary embolism venous thromboembolism, factor VII factor XI , venous thromboembolism venous thromboembolism, circulating fibrinogen levels

Definition and Scope of Deep Vein Thrombosis

Deep vein thrombosis (DVT) is precisely defined as the formation of a blood clot within a deep vein, most commonly occurring in the deep veins of the arms or legs.^[12]It is a critical component of the broader medical condition known as Venous Thromboembolism (VTE), which encompasses both DVT and pulmonary embolism (PE).^[4]Pulmonary embolism, a potentially life-threatening complication, arises when a portion of a DVT dislodges and travels through the bloodstream to obstruct an artery in the lungs.^[12] The overarching term “thrombosis” refers to the pathological formation of a blood clot (thrombus) inside a blood vessel, which can be further categorized into venous or arterial thrombosis based on the affected circulatory system.^[20]Operationally, DVT is often identified in large-scale research studies and clinical settings through a doctor’s diagnosis, sometimes relying on self-reported confirmation of “a blood clot in your arms or legs (deep-vein thrombosis or DVT)”.^[12] This conceptual framework establishes DVT as a specific manifestation of venous clotting with significant clinical implications.

Classification and Clinical Context of Venous Thromboembolism

DVT is classified as a primary subtype of Venous Thromboembolism (VTE), representing a spectrum of conditions characterized by the formation of blood clots within the venous system.^[4]The most significant distinction within VTE is between DVT, predominantly affecting the deep veins of the limbs, and pulmonary embolism (PE), which involves the migration of clots to the pulmonary vasculature.^[12] While DVT is typically considered a categorical diagnosis for its presence, its clinical presentation can vary depending on location (e.g., upper extremity versus lower extremity DVT) and underlying precipitants, highlighting the need for nuanced patient assessment.

The nosological positioning of DVT within thrombotic disorders acknowledges shared pathophysiological mechanisms related to blood coagulation and fibrinolysis. Clinical management and prevention strategies are guided by standardized classification systems and evidence-based clinical practice guidelines, such as those issued by the American College of Chest Physicians (ACCP).^[21]These guidelines are crucial for effective risk stratification and for directing appropriate interventions, particularly in high-risk scenarios such as postoperative venous thromboembolism.^[22] thereby informing patient care and research criteria.

Diagnostic Approaches and Risk Stratification

The diagnosis and comprehensive risk assessment of DVT integrate clinical evaluation, biomarker analysis, and an understanding of predisposing factors. Clinicians often employ pretest probability scores, such as the Wells score, to guide further diagnostic investigations.^[23] while general risk assessment tools are utilized to inform preventive strategies.^[24]Key clinical risk factors identified for DVT include increasing age, female sex, elevated Body Mass Index (BMI), a history of smoking, diabetes mellitus, and a personal history of cancer.^[4]Notably, obesity has been robustly implicated as a causal risk factor for DVT through various epidemiological and Mendelian randomization studies.^[4] Beyond clinical indicators, genetic and biochemical markers play an increasingly important role in both diagnosis and risk stratification. Genetic variations within pathways governing anticoagulation, procoagulation, fibrinolysis, and innate immunity are recognized as risk factors for VTE.^[25] Specific genetic loci, including ZFPM2, F11, and regions on chromosomes 1q24.2 and 9q, have been associated with altered VTE susceptibility.^[4] Furthermore, certain biomarkers, such as low levels of tissue factor pathway inhibitor (TFPI), are linked to an increased risk of thrombosis.^[26] and genetic variations in the fibrinogen gamma gene can specifically elevate the risk of DVT.^[27] underscoring the complex, multifactorial etiology of the condition.

Genetic Susceptibility

Deep vein thrombosis (DVT) is a complex condition with a significant genetic component, with heritability estimated to be approximately 30%.^[28]Familial segregation studies have demonstrated the clustering of venous thromboembolism within families, highlighting the role of inherited factors.^[29] Key Mendelian forms of thrombophilia, such as common variants in the FV (Factor V) and ABO loci, are recognized as strong contributors to DVT risk, influencing the coagulation cascade.^[9]Beyond these high-impact variants, a polygenic architecture contributes to risk, with numerous single nucleotide polymorphisms (SNPs) identified through genome-wide association studies (GWAS).

These GWAS have uncovered several susceptibility loci for DVT. For instance, variants within the F11 locus have been associated with DVT risk, impacting coagulation factor XI.^[3] Other identified loci include ZFPM2.^[4] specific regions on chromosomes 1q24.2 and 9q.^{[1], [2]} and genes like TSPAN15 and SLC44A2.^[19] Genetic variations within the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways, such as the KNG1 Ile581Thr variant.^[30] polymorphisms in the fibrinogen gamma (FGG) gene.^{[27], [31]} and the PROCR Ser219Gly variant , all contribute to an individual’s predisposition to DVT.^[25] The interplay between these multiple genetic factors, including potential gene-gene interactions, further complicates the genetic landscape of DVT risk.

Environmental and Lifestyle Risk Factors

Environmental and lifestyle factors play a critical role in the development of deep vein thrombosis, often interacting with an individual’s genetic background. A prominent lifestyle risk factor is obesity, which has been identified as a causal risk factor for DVT.^{[4], [5]}Studies examining anthropometry and body fat have consistently linked higher body mass to an increased incidence of venous thromboembolism.^[32]These findings suggest that obesity contributes to a prothrombotic state through mechanisms such as chronic inflammation, endothelial dysfunction, and alterations in hemostatic factors.

Beyond obesity, several other environmental and acquired factors are recognized contributors to DVT. These include periods of prolonged immobility, major surgery, trauma, and certain medical treatments.^{[16], [33]}The use of certain medications, such as oral contraceptives and hormone replacement therapy, is also associated with an elevated risk of DVT due to their impact on coagulation protein levels.^[16]While specific details on diet, environmental exposures, socioeconomic factors, or geographic influences are not extensively detailed in the researchs, the overall understanding is that these broader environmental determinants contribute to the multifactorial nature of DVT.^[28]

Interacting and Modifying Factors

Deep vein thrombosis often arises from a complex interplay between an individual’s genetic predisposition and various environmental triggers, illustrating significant gene-environment interactions. For instance, the association between theZFPM2locus and DVT risk is implicated alongside obesity, suggesting that genetic vulnerabilities can be exacerbated or triggered by specific lifestyle factors.^[4] This highlights how an individual’s genetic makeup may modify their susceptibility to environmental influences, leading to a higher or lower risk profile than either factor alone would suggest.

Furthermore, several other factors modify the risk of DVT. Comorbidities such as cancer significantly increase the likelihood of developing DVT, creating a hypercoagulable state.^[16]While the relationship between diabetes mellitus and DVT has been investigated, its role as an independent risk factor is a subject of ongoing study.^[34] Age is another critical modifying factor, with the risk of DVT generally increasing with advancing age.^{[35], [36]} These diverse factors, ranging from inherited predispositions to acquired conditions and demographic changes, collectively contribute to the multifaceted etiology of DVT.

Pathophysiology of Thrombus Formation

Deep vein thrombosis (DVT) is a complex condition characterized by the formation of a blood clot, or thrombus, within a deep vein, most commonly in the legs. The underlying mechanisms of DVT are often explained by Virchow’s triad, which highlights three primary contributing factors: blood stasis, vascular endothelial injury, and a state of hypercoagulability.^[37] Blood stasis, referring to sluggish blood flow, allows coagulation factors to accumulate and inhibits the clearance of activated factors, thereby promoting clot formation. Endothelial injury, whether from trauma, surgery, or inflammation, exposes subendothelial collagen and tissue factor, initiating the extrinsic pathway of coagulation and providing a surface for platelet adhesion and activation.

Hypercoagulability represents a disruption in the delicate balance of the body’s hemostatic system, leading to an increased propensity for clotting. This imbalance can arise from an excess of procoagulant factors, a deficiency in anticoagulant proteins, or impaired fibrinolysis, the process by which clots are broken down.^[38]The interplay of these factors leads to an uncontrolled activation of the coagulation cascade, culminating in the conversion of fibrinogen to fibrin and the formation of a stable thrombus. While the primary site of DVT is typically in the deep veins, particularly in the lower extremities, the most serious systemic consequence is pulmonary embolism, where a part of the thrombus breaks off and travels to the lungs.^[39]

Molecular and Cellular Components of Hemostasis

The formation and dissolution of a thrombus involve a sophisticated network of key biomolecules and cellular functions. Central to the procoagulant pathway are proteins like Factor V and prothrombin, where specific genetic variations can significantly increase DVT risk. A common mutation in blood coagulation factor V, known as Factor V Leiden, leads to resistance to activated protein C (APC), a natural anticoagulant, thereby enhancing thrombin generation.^[40]Similarly, a genetic variation in the 3’-untranslated region of the prothrombin gene can result in elevated plasma prothrombin levels, increasing the availability of thrombin and promoting clot formation.^[41] Fibrinogen, another critical protein, is essential for forming the fibrin meshwork of the clot, and genetic variations in the fibrinogen gamma gene (FGG), such as the FGG 10034C>T polymorphism or 3’-end polymorphisms, can alter fibrinogen levels or function, influencing DVT susceptibility.^[31] Anticoagulant and fibrinolytic pathways are equally crucial in maintaining hemostatic balance. Key anticoagulant proteins include Protein C, Antithrombin, and Tissue Factor Pathway Inhibitor (TFPI). Low levels of TFPI are associated with an increased risk of venous thrombosis, highlighting its role in regulating the extrinsic coagulation pathway.^[42] Genetic variations influencing plasma levels of Protein C, Antithrombin, and von Willebrand factor (vWF) also contribute to thrombosis risk.^[43] The kininogen gene (KNG1), particularly the Ile581Thrvariant, has also been implicated in susceptibility to venous thromboembolism.^[30]Furthermore, cellular processes, such as monocyteCXCR2-mediated activity, play a role in the resolution of deep vein thrombosis.^[44] while overexpression of plasminogen activator-1 (PAI-1) can decrease post-thrombotic vein wall fibrosis, indicating its involvement in tissue remodeling after a thrombotic event.^[45]

Genetic Basis of Deep Vein Thrombosis

Deep vein thrombosis is recognized as a multifactorial disorder with significant genetic contributions, alongside environmental influences.^[38] Extensive genome-wide association studies (GWAS) have identified numerous genetic variants and loci associated with an increased risk of DVT, underscoring its polygenic nature.^[8] These studies have pinpointed susceptibility loci on chromosomes 1q24.2 and 9q, and genes such as TSPAN15 and SLC44A2.^[46] Other significant genetic associations include the ZFPM2 locus and the F11 locus, both implicated in DVT risk.^[4] The BAI3locus has also been associated with early-onset venous thromboembolism.^[47]Genetic variations within pathways governing anticoagulation, procoagulation, fibrinolysis, and innate immunity collectively act as risk factors for venous thromboembolism.^[25] For instance, the ABO blood group locus is known to influence DVT risk, demonstrating how common genetic variations can impact complex traits.^[48]Beyond individual gene variants, the familial segregation of venous thromboembolism highlights the inherited component of this disease.^[29] Researchers are also exploring gene-gene interactions as well as the concept of “missing heritability” in complex diseases like DVT, suggesting that many genetic factors, including regulatory elements and subtle gene expression patterns, remain to be fully elucidated.^[49]

Systemic and Environmental Modulators

Beyond the direct mechanisms of coagulation, various systemic and environmental factors significantly modulate the risk and progression of deep vein thrombosis. Obesity, for instance, has been robustly identified as a causal risk factor for DVT.^[4] Adiposity can induce a prothrombotic state through multiple pathways, including chronic low-grade inflammation, altered lipid metabolism, and changes in the levels of various hemostatic factors. These systemic effects contribute to the overall hypercoagulability and endothelial dysfunction observed in obese individuals, increasing their susceptibility to clot formation.

The interplay between genetic predispositions and environmental exposures is crucial in determining an individual’s overall risk. For example, the genetic variations that influence hemostatic protein levels can be exacerbated or mitigated by lifestyle factors and co-morbidities. The systemic consequences of DVT extend beyond the initial clot, potentially leading to post-thrombotic syndrome, characterized by chronic pain, swelling, and skin changes in the affected limb, often involving vein wall fibrosis.^[45] Thus, DVT is not merely a localized event but a systemic challenge influenced by a broad spectrum of biological and environmental interactions.

Dysregulation of Hemostatic and Fibrinolytic Pathways

Deep vein thrombosis (DVT) arises from an imbalance in the intricate hemostatic system, involving both procoagulant and anticoagulant pathways alongside fibrinolysis. Genetic variations within these systems significantly influence DVT risk, with specific loci identified as susceptibility factors.^{[8], [36]} For instance, variants in the F11 gene, encoding Factor XI, are associated with DVT, highlighting its role in the intrinsic coagulation cascade.^[50] Similarly, the KNG1 Ile581Thr variant has been linked to venous thrombosis susceptibility, suggesting a role for the contact activation pathway.^[30] Compounding procoagulant tendencies, reduced activity or levels of natural anticoagulants like Tissue Factor Pathway Inhibitor (TFPI) markedly increase the risk of venous thrombosis by failing to adequately suppress the initiation of coagulation.^{[42], [51], [52]} Furthermore, genetic variations in the fibrinogen gamma gene can elevate DVT risk by altering plasma fibrinogen gamma’ levels, impacting clot structure and stability.^[27] The fibrinolytic system, responsible for breaking down clots, also plays a critical role, with the ATF6-tPA pathway in hepatocytes contributing to systemic fibrinolysis, a process that can be repressed by DACH1.^[53] Genome-wide association studies have also identified TSPAN15 and SLC44A2as susceptibility loci for venous thromboembolism, implicating additional, less characterized regulatory mechanisms in coagulation.^[54]

Inflammatory Signaling and Immune Cell Responses

Inflammation is a critical component of DVT pathogenesis, with immune cells and their signaling pathways significantly contributing to thrombus formation, propagation, and resolution. Receptor activation on monocytes, specifically through CXCR2 (C-X-C motif chemokine receptor 2), is crucial for modulating DVT resolution in experimental models.^[44] Similarly, targeted deletion of CCR2 (C-C motif chemokine receptor 2) has been shown to impair DVT resolution, highlighting the importance of chemokine signaling in the immune response to thrombosis.^[44] Endotoxemia, an inflammatory state, can augment venous thrombosis in murine models in a manner dependent on TLR-4 (Toll-like receptor 4) and ICAM-1 (Intercellular Adhesion Molecule 1), indicating a direct link between innate immunity and thrombotic risk.^[4] These receptor activations initiate intracellular signaling cascades that regulate gene expression and cellular function, contributing to the inflammatory milieu within the thrombosed vein. For instance, Interleukin-6 (IL-6), a pro-inflammatory cytokine, is considered a potential therapeutic target for post-thrombotic syndrome, suggesting its involvement in the sustained inflammatory and remodeling processes following DVT.^[55] The coordinated action of these signaling pathways and immune cells underscores a complex feedback loop where inflammation both contributes to and is perpetuated by the presence of a thrombus, influencing its stability and eventual fate.

Metabolic and Genetic Modulators of Thrombotic Risk

Systemic metabolic conditions and broad genetic predispositions significantly modulate an individual’s susceptibility to DVT, acting as overarching regulatory mechanisms that influence local pathway dysregulation. Obesity, for example, is firmly established as a causal risk factor for deep vein thrombosis, impacting various metabolic pathways that contribute to a prothrombotic state.^{[4], [5], [32], [56]} This metabolic dysregulation can alter hemostatic factor levels, endothelial function, and inflammatory responses, creating an environment conducive to clot formation.

Genome-wide association studies (GWAS) have been instrumental in identifying novel genetic loci that confer risk for venous thromboembolism, including theZFPM2 locus.^[4] and regions on chromosomes 1q24.2 and 9q.^[2]These findings suggest that multiple genes, likely involved in diverse biological processes, contribute to the polygenic nature of DVT risk. Furthermore, there is a recognized genetic overlap between DVT and arterial vascular disease, indicating pathway crosstalk and shared underlying genetic mechanisms that impact vascular health broadly.^{[4], [20]} Even anthropometric traits like genetically determined height have been implicated in VTE risk, further illustrating how systemic, complex genetic factors can hierarchically regulate an individual’s overall thrombotic predisposition.^{[56], [57]}

Vascular Remodeling and Impaired Thrombus Resolution

The resolution of a deep vein thrombus is a dynamic process involving fibrinolysis, inflammation, and subsequent vein wall remodeling, with dysregulation in these mechanisms often leading to chronic complications. The balance between urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) is critical in orchestrating vein wall remodeling during experimental DVT, influencing the degradation of the thrombus and the structural integrity of the vessel.^[4]Overexpression of PAI-1, for instance, has been shown to decrease experimental post-thrombotic vein wall fibrosis, highlighting its regulatory role in tissue repair and scar formation.^[45]Cellular signaling pathways involving chemokine receptors play a dual role in both thrombus resolution and subsequent fibrotic injury. While monocyteCXCR2-mediated activity is essential for DVT resolution, the targeted deletion of CCR2 impairs this process, signifying their importance in recruiting cells necessary for clot clearance.^[44] Conversely, the deletion of CCR7(C-C motif chemokine receptor 7) promotes fibrotic injury in experimental post-thrombotic vein wall remodeling, suggesting that an inappropriate or exaggerated healing response can lead to pathological changes like fibrosis, which is a hallmark of post-thrombotic syndrome.^[58] These intricate interactions among fibrinolytic enzymes, inflammatory cells, and vascular repair mechanisms determine the emergent properties of thrombus resolution and the long-term health of the affected vein.

Clinical Relevance

Deep vein thrombosis (DVT), a component of venous thromboembolism (VTE), represents a significant public health concern with substantial morbidity and mortality globally, impacting millions of individuals annually.^[59]The clinical relevance of DVT extends from its acute presentation and potential for life-threatening complications, such as pulmonary embolism (PE), to its long-term sequelae like post-thrombotic syndrome.^[12] Understanding and managing DVT requires a multifaceted approach encompassing accurate risk stratification, precise diagnostic and therapeutic strategies, and consideration of associated comorbidities.

Risk Stratification and Prognostic Implications

Effective risk stratification is crucial for identifying individuals at high risk of DVT and guiding personalized prevention strategies. Established clinical risk assessment tools, such as the Caprini score and pretest probability assessments like the Wells score, are utilized to evaluate a patient’s likelihood of developing VTE, particularly in surgical settings where postoperative VTE risk is elevated.^[24]Beyond traditional clinical factors such as age, prior VTE, immobility, and estrogen therapy, genetic predispositions play a significant role in DVT susceptibility.^[60] For instance, the Factor V Leiden mutation is a well-known genetic risk factor for thrombosis.^[40] Recent genome-wide association studies (GWAS) have further expanded this understanding, identifying numerous additional susceptibility loci, including those on chromosomes 1q24.2 and 9q, and specific genes like ZFPM2, TSPAN15, SLC44A2, and F11.^[2]The integration of these genetic insights, potentially through polygenic risk scores, holds promise for refining risk prediction and enabling more targeted prophylactic interventions, thereby influencing long-term patient outcomes and disease progression.^[28]

Diagnostic and Therapeutic Strategies

The clinical application of DVT knowledge is paramount for timely diagnosis and appropriate treatment selection. The initial assessment often involves evaluating clinical probability, followed by diagnostic imaging, as outlined in evidence-based guidelines from organizations like the American College of Chest Physicians.^[21] For patients undergoing surgery, risk assessment tools help guide the selection of thromboprophylaxis, which is essential given the substantial risk of postoperative VTE.^[24] Treatment decisions for confirmed DVT involve selecting appropriate anticoagulant therapies, with duration often tailored based on the patient’s risk of recurrence and bleeding.^[39] Ongoing monitoring strategies are also critical to assess treatment response, manage potential complications, and identify individuals who may benefit from extended anticoagulation to prevent recurrent events and mitigate long-term sequelae.

Associated Conditions and Long-term Morbidity

Deep vein thrombosis is closely linked with several associated conditions and can lead to significant long-term morbidity. The most acute and life-threatening complication is pulmonary embolism (PE), which occurs when a part of the thrombus detaches and travels to the lungs, contributing to VTE-related mortality.^[59]Beyond acute events, DVT can lead to chronic venous disease and post-thrombotic syndrome, characterized by persistent leg pain, swelling, and skin changes, which impose a considerable economic and health burden.^[7]Furthermore, DVT is associated with several comorbidities; for instance, obesity is increasingly recognized as a causal risk factor, impacting both DVT incidence and severity.^[4]Other conditions, such as cancer and potentially diabetes mellitus, are also linked to an increased risk of VTE, highlighting the complex interplay of various factors in thrombosis development.^[60]Research also suggests a genetic overlap between VTE and arterial vascular disease, indicating shared underlying biological pathways that may influence broader cardiovascular health.^[28]

Frequently Asked Questions About Deep Vein Thrombosis

These questions address the most important and specific aspects of deep vein thrombosis based on current genetic research.

---

1. My parents had DVT; am I likely to get it too?

Yes, DVT has a significant genetic component. Research shows that about 50-60% of your risk for venous thromboembolism (which includes DVT) can be inherited. Specific gene variations, like those in theF11 locus, or the FV and ABO loci, can significantly increase your susceptibility.

2. Does my weight really make me more likely to get clots?

Yes, absolutely. Studies have identified obesity as a causal risk factor for DVT. Carrying excess weight can alter your body’s clotting mechanisms and blood flow, increasing your likelihood of developing a clot.

3. Why do some people get clots from long flights, but others don’t?

It’s because your genetics play a role in how your blood clots. While prolonged sitting, like on a long flight, can disrupt blood flow and increase anyone’s risk, individuals with specific genetic variations are more susceptible to clot formation under these conditions.

4. Does my ethnic background affect my DVT risk?

Yes, your ancestry can influence your DVT risk. Many large genetic studies have focused primarily on people of European descent, meaning that the identified risk variants may not apply directly or completely to other populations. Research is still expanding to understand genetic risks in diverse groups like African-Americans.

5. My sibling is healthy but I got DVT; why the difference?

Even within families, genetic predispositions can vary, and environmental factors play a role too. While DVT has high heritability (50-60%), it’s a complex condition where interactions between your unique genetic makeup and lifestyle choices determine your individual risk.

6. Could a genetic test tell me if I’ll get DVT?

A genetic test can identify some known, strong genetic risk factors for DVT, like specific variations in the FV and FIIgenes, or deficiencies in anti-thrombin, protein C, or protein S. However, for many common DVT cases, numerous genetic variants with smaller effects contribute, and current tests don’t capture the full picture.

7. Can I prevent DVT if it runs in my family, by exercising?

While genetics significantly influence your risk, lifestyle factors like regular exercise are crucial. Exercise improves blood flow and can counteract some of the tendencies for blood to clot, especially when combined with managing other risk factors like obesity. It’s a powerful tool even with a family history.

8. Are some people just naturally more prone to blood clots?

Yes, some individuals have a higher natural tendency for their blood to clot due to their genetic makeup. This is a core part of what makes DVT heritable, with specific genetic variants influencing the complex coagulation pathways in your body.

9. If DVT runs in my family, should I worry when I’m young?

If DVT runs strongly in your family, especially at a younger age, it’s wise to be aware. This could indicate a higher likelihood of inheriting specific genetic mutations, like those in FV Leiden or FII 20210A, which are known to significantly increase risk.

10. Does my blood type affect my chance of getting DVT?

Yes, surprisingly, your blood type can influence your DVT risk. Genetic studies have consistently linked variants in the ABOblood group locus to venous thromboembolism, making certain blood types more susceptible than others.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Heit, J. A., et al. “A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q.”J Thromb Haemost 10 (2012): 1521–1531.

[2] Tang W, et al. “A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.”Genet Epidemiol, vol. 37, 2013, pp. 251–62.

[3] Li Y, et al. “Genetic variants associated with deep vein thrombosis: the F11 locus.”J Thromb Haemost, vol. 7, 2009, pp. 1802–8.

[4] Klarin D, et al. “Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies theZFPM2Locus and Implicates Obesity as a Causal Risk Factor.”Circ Cardiovasc Genet, vol. 10, no. 2, 2017. PMID: 28373160.

[5] Klovaite J, et al. “Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study.”J Intern Med, vol. 277, 2015, pp. 573–84.

[6] Beckman MG, Hooper WC, Critchley SE, Ortel TL. “Venous thromboembolism: a public health concern.”Am J Prev Med, vol. 38, 2010, pp. S495–501.

[7] MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. “Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.”Am J Health Syst Pharm, vol. 63, 2006, pp. S5–15.

[8] Germain M, Saut N, Greliche N, et al. “Genetics of venous thrombosis: insights from a new genome wide association study.” PLoS One, vol. 6, no. 9, 2011, e25581. PMID: 21980494.

[9] Tregouet DA, Heath S, Saut N, et al. “Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach.” Blood, vol. 113, 2009, pp. 5298–5303. PMID: 19278955.

[10] Alcalay, A., et al. “Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.”J. Clin. Oncol. 24.7 (2006): 1112–1118.

[11] Heit JA, et al. “Identification of unique venous thromboembolism-susceptibility variants in African-Americans.”Thromb Haemost, vol. 117, no. 5, 2017, pp. 936–945. PMID: 28203683.

[12] Hinds DA, et al. “Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.” Hum Mol Genet, vol. 25, 2016, pp. 1867–1874. PMID: 26908601.

[13] Benjamin EJ, Rice KM, Arking DE, et al. “Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry.” Nat Genet, vol. 41, 2009, pp. 879–881. PMID: 19597492.

[14] Manolio TA, Collins FS, Cox NJ, et al. “Finding the missing heritability of complex diseases.” Nature, vol. 461, 2009, pp. 747–753. PMID: 19812669.

[15] Yang J, Bakshi A, Zhu Z, et al. “Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index.”Nat Genet, vol. 47, 2015, pp. 1114–1120. PMID: 26343388.

[16] Rosendaal FR. “Venous thrombosis: a multicausal disease.”Lancet, vol. 353, 1999, pp. 1167–1173. PMID: 10218991.

[17] Morange PE, Tregouet DA. “Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?”Br J Haematol, vol. 148, 2010, pp. 495–506. PMID: 20039801.

[18] Tang, W et al. “Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.”Am J Hum Genet, 2012, 90:492–501.

[19] Germain, M et al. “Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.”Am J Hum Genet, 2015, 96:532–542.

[20] Prandoni, P. “Venous and arterial thrombosis: two aspects of the same disease?”Eur J Intern Med, vol. 20, no. 7, 2009, pp. 660–661.

[21] American College of Chest Physicians. “Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest, vol. 141, no. 2 Suppl, 2012, pp. e227S–e277S.

[22] Gangireddy, C., et al. “Risk factors and clinical impact of postoperative symptomatic venous thromboembolism.”J. Vasc. Surg. 45.2 (2007): 335–341.

[23] Wells, P. S., et al. “Value of assessment of pretest probability of deep-vein thrombosis in clinical management.”Lancet 350.9094 (1997): 1795–1798.

[24] Caprini, J. A. “Risk assessment as a guide for the prevention of the many faces of venous thromboembolism.”Am. J. Surg. 199.1 (2010): S3–S10.

[25] Heit, J. A., et al. “Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism.”J Thromb Haemost 9 (2011): 1133–42.

[26] Javanmard, S. H., et al. “Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis.” Advanced Biomedical Research, vol. 4, 2015, p. 6.

[27] Uitte de Willige, S. et al. “Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma’ levels.” Blood, vol. 106, 2005, pp. 4176–4183.

[28] Klarin, D et al. “Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease.”Nat Genet, 2019, 51:1075–1081.

[29] Heit, J. A., et al. “Familial segregation of venous thromboembolism.”J Thromb Haemost 2 (2004): 731–736.

[30] Morange, P. E., et al. “KNG1 Ile581Thr and susceptibility to venous thrombosis.” Blood, vol. 117, no. 13, 2011, pp. 3692–3694.

[31] Grunbacher, G. et al. “The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis.” Thromb Res, vol. 121, 2007, pp. 33–36.

[32] Severinsen, M. T., et al. “Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study.”Circulation 120 (2009): 1850–7.

[33] Cushman, Mary. “Epidemiology and risk factors for venous thrombosis.” Seminars in Hematology, vol. 44, no. 2, 2007, pp. 62–69.

[34] Heit, J. A., et al. “Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study.”Arterioscler Thromb Vasc Biol. 29 (2009): 1399–405.

[35] Zoller, Bengt, et al. “Age- and gender-specific familial risks for venous thromboembolism: a nationwide epidemiological study based on hospitalizations in Sweden.”Circulation, vol. 124, no. 9, 2011, pp. 1012–1020.

[36] Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJI. “Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.”Arch Intern Med, vol. 160, 2000, pp. 809–15.

[37] Kyrle, P.A. and Eichinger, S. “Is Virchow’s triad complete?” Blood, vol. 114, 2009, pp. 1138–9.

[38] Rosendaal, F.R. “Venous thrombosis: a multicausal disease.”Lancet, vol. 353, 1999b, pp. 1167–1173.

[39] Hirsh, J. and Hoak, J. “Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association.”Circulation, vol. 93, 1996, pp. 2212–2245.

[40] Bertina, R. M., et al. “Mutation in blood coagulation factor V associated with resistance to activated protein C.”Nature 369.6475 (1994): 64–67.

[41] Poort, S.R. et al. “A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.” Blood, vol. 88, 1996, pp. 3698–703.

[42] Amini-Nekoo, A. et al. “Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis.” Br. J. Haematol., vol. 113, 2001, pp. 537–543.

[43] Folsom, A.R. et al. “Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study.”Arterioscler Thromb Vasc Biol, vol. 22, 2002, pp. 1018–1022.

[44] Henke, P. K., et al. “Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model.”Arterioscler Thromb Vasc Biol, vol. 24, no. 6, 2004, pp. 1130–7.

[45] Obi, A. T., et al. “Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.”J Thromb Haemost, vol. 12, no. 8, 2014, pp. 1353–63.

[46] Germain, M. et al. “Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism in European ancestry.”Nat Genet, vol. 41, 2009, pp. 879–881.

[47] Antoni, G. et al. “A multi-stage multi-design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism.”J Thromb Haemost, vol. 8, 2010, pp. 2671–2679.

[48] Greliche, N. et al. “The FV and ABO loci to VTE risk: results from a GWAS approach.” Blood, vol. 113, 2009, pp. 5298–5303.

[49] Cordell, H.J. “Detecting gene-gene interactions that underlie human diseases.” Nat Rev Genet, vol. 10, 2009, pp. 392–404.

[50] Bezemer, I.D., Bare, L.A., Doggen, C.J., Arellano A.R., Tong C., Rowland C.M., Catanese J., Young B.A., Reitsma P.H., Devlin J.J. et al. “Gene variants associated with deep vein thrombosis.”JAMA, 2008, 299:1306–1314.

[51] Hoke, M. et al. “Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.”Thromb. Haemost., vol. 94, 2005.

[52] Dahm, A. et al. “Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis.” Blood, vol. 101, 2003, pp. 4387–4392.

[53] Spiezia, L., et al. “Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis.” Thromb Haemost, vol. 116, no. 4, 2016, pp. 702-3.

[54] Smith, N. L., et al. “Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.”Am J Hum Genet, vol. 96, no. 4, 2015, pp. 532–42.

[55] Wojcik, B. M., et al. “Interleukin-6: a potential target for post-thrombotic syndrome.” Ann Vasc Surg, vol. 25, no. 2, 2011, pp. 229–39.

[56] Borch, K. H., et al. “Joint effects of obesity and body height on the risk of venous thromboembolism: the Tromso Study.”Arterioscler Thromb Vasc Biol, vol. 31, no. 6, 2011, pp. 1439–1444.

[57] Nelson, C. P., et al. “Genetically determined height and coronary artery disease.”N Engl J Med, vol. 372, no. 17, 2015, pp. 1608–1618.

[58] Laser, A., et al. “Deletion of cysteine-cysteine receptor 7 promotes fibrotic injury in experimental post-thrombotic vein wall remodeling.”Arterioscler Thromb Vasc Biol, vol. 34, no. 2, 2014, pp. 377–85.

[59] Horlander, K. T., D. M. Mannino, and K. V. Leeper. “Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data.”Arch. Intern. Med. 163.14 (2003): 1711–1717.

[60] Anderson, F. A. Jr., and F. A. Spencer. “Risk factors for venous thromboembolism.”Circulation 107 (2003): I9–16.